Fibrostatin (www.fibrostatin.com) announces a funding round to initiate the regulatory development of its innovative drug candidate T12 in patients with advanced solid tumors (drug resistant and metastatic), with special focus on patients with lung cancer who suffer from recurrence after surgery and chemotherapy.
Lung cancer is one of the deadliest diseases nowadays, with an annual worldwide incidence of about 2 million new cases according to the IARC (International Agency for Research on Cancer) of the WHO (World Health Organization). Drug resistance and metastasis, or tumor's ability to invade healthy tissues, are the usual end consequence in the development of these tumors. The life expectancy of patients with resistant and metastatic lung cancer is reduced to months. Current studies indicate that around 85% of lung tumors will metastasize at some point during their development.
T12 is innovative because targets the tumor microenvironment. None of the treatments currently approved for Cancer is directed against the tumor microenvironment. Treatment with T12 inhibits GPBP (Goodpasture Antigen-Binding Protein), a protein kinase which directs the formation of extracellular collagen that protects invasive tumor cells against conventional chemotherapy.
T12 is a compound designed by the company's scientists to treat Advanced Cancer without causing adverse clinical effects, as it has been demonstrated in animal models for Advanced Lung and Breast Cancer.
The Company aims to address toxicity studies in animal species under the supervision of the Spanish Agency of Drugs and Health Products (AEMPS) (Regulatory Preclinical Phase), and plans to initiate a Phase 1 in patients with advanced solid tumors at the INCLIVA Health Research Institute.
FIBROSTATIN, S.L. (www.fibrostatin.com) is a biotechnology company founded in 2005, arising from the discovery by scientists of Centro de Investigación Príncipe Felipe (CIPF) and the University of Valencia (UV) of the human protein GPBP (Goodpasture Antigen-Binding Protein) and of its involvement in the development of diseases such as drug-resistant cancer, autoimmunity, organ fibrosis and type 2 diabetes. The company develops its R & D activities in the Scientific Park of the University of Valencia, Spain.
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del...
A study published in Pediatric Neurology provides a better understandi...
